CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (50,882)	$ (36,802)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to the sales of future royalties	(10,460)	(15,508)
Non-cash interest expense on liabilities related to the sales of future royalties	4,974	5,531
Loss from equity method investment	4,461	0
Stock-based compensation	3,898	6,000
Depreciation and amortization expense	426	1,607
Provision for net realizable value of inventory	0	1,006
Amortization of premiums (discounts), net	(1,324)	(3,063)
Changes in operating assets and liabilities:
Accounts receivable	0	(2,412)
Inventory	0	(1,143)
Operating leases, net	(1,813)	(2,958)
Other assets	(5,958)	(976)
Accounts payable	6,410	(988)
Accrued expenses	1,215	1,818
Net cash used in operating activities	(49,053)	(47,888)
Cash flows from investing activities:
Purchases of investments	(24,931)	(105,059)
Maturities of investments	69,319	124,474
Purchases of property equipment	(2)	(157)
Payment of transaction costs and working capital adjustment from the sale of the Huntsville manufacturing facility	(697)	0
Net cash provided by investing activities	43,689	19,258
Cash flows from financing activities:
Proceeds from shares issued under equity compensation plans	7	3
Proceeds from issuance of pre-funded warrant	0	30,000
Proceeds from sale of future royalties	0	15,000
Repurchase of common stock from Bristol-Myers Squibb	0	(3,000)
Net cash provided by financing activities	7	42,003
Effect of foreign exchange rates on cash and cash equivalents	(1)	(8)
Net increase (decrease) in cash and cash equivalents	(5,358)	13,365
Cash and cash equivalents at beginning of period	44,252	35,277
Cash and cash equivalents at end of period	$ 38,894	$ 48,642